Compare Cytokinetics Inc (CYTK) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Marathon Petroleum Corp — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Marathon Petroleum Corp trades at $455.03 (market cap $130.12B). The key difference: Marathon Petroleum Corp is far larger — about 15.1× Cytokinetics Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Marathon Petroleum Corp for 54 Days on average.
| CYTK | MPC | |
|---|---|---|
Market Cap | $8.62B | $130.12B |
Volume | 2,594,626 | 2,749,647 |
Sector | Health | Energy |
52-Week High | $87.26 | $463.34 |
52-Week Low | $54.76 | $162.63 |
Typical Hold Time | 19 Days | 54 Days |
Enterprise Value | $8.72B | $156.64B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Marathon Petroleum (MPC) trades at $463.34, up 4.77% with strong bullish momentum. The stock shows robust technical strength with consistent earnings beats and favorable valuation metrics including P/E of 16.07 and P/S of 0.9. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions create uncertainty. The company maintains solid profitability with 5.57% net margin and exceptional 47.9% ROE.
MPC presents a compelling investment case with strong fundamentals and analyst support, though near-term risks include regulatory uncertainty and volatile energy markets. With 75.76% analyst buy ratings and $420.30 consensus target, the stock offers growth potential despite trading above target. Investors should weigh strong cash flow generation against exposure to energy policy changes and margin compression risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
